Clinical Trials
13 trialsNCT03155620 2026-06-01
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03213678 2026-04-21
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT02784795 2025-08-21
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT03675893 2025-06-15
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT02549989 2023-02-22
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01655225 2022-04-08
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02407054 2021-05-11
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02443337 2020-12-09
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT02079636 2020-09-11
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1 Completed
NCT02124148 2020-04-01
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02981342 2019-11-20
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Eli Lilly and Company
Phase 2 Completed
NCT02536586 2018-07-24
A Study of LY3023414 in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed